Belgium: Johnson & Johnson has announced that the European Commission has extended the marketing authorisation for TREMFYA ...

Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1The decision is supported by the ...

AbbVie to present data from multiple studies of Rinvoq, Humira & Skyrizi at the 2019 ACR/ARP) meeting: North Chicago, Illionis Tuesday, November 5, 2019, 16:00 Hrs [IST] AbbVie, a ...

David Ozeri, MD, FACP, FACR, is a rheumatologist and current researcher at Sheba Medical Center in Israel. He worked at Kings County Hospital Center and treated veterans at New York Harbor Healthcare ...

In 2025, the latest biosimilar policy developments included bipartisan efforts to enhance affordability and reduce barriers ...

SaveHealth reports on psoriatic arthritis medications, detailing options like DMARDs, biologics, and NSAIDs, including their ...

ASAS-PerSpA study finds Japanese patients with axial psoriatic arthritis have lower disease activity and better function than ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — The novel, oral tyrosine kinase 2 inhibitor deucravacitinib yielded durable ACR20 response rates ...

People with psoriatic arthritis are at higher risk of catching certain infections — and having more severe symptoms. Vaccines can help keep you safe.

Sustained long-term safety data for tildrakizumab strengthens the positioning of IL-23 inhibitors as a preferred choice, especially for patients with comorbidities or a history of infection, and ...

Exposure to occupational inhalants such as silica, pesticides, asbestos, solvents, fertilizers, animal dust and engine ...

Gastroenterologist Dr. Saurabh Sethi highlights that early health changes are often missed due to our fast-paced lives. He urges attention to subtle body signals like brain fog, post-meal fatigue, and ...